Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × atezolizumab × CNS × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 9 Brain Neoplasms 5 Gliosarcoma 2 Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Carcinoma, Anaplastic 1 Small Cell Lung Carcinoma 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Melanoma 1 HER2-positive Metastatic Breast Cancer 1 Astrocytoma 1 Adenocarcinoma 1

Interventions

pertuzumab 1 atezolizumab 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting

19 enrolled 26 charts

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡